Phase 4
Completed N=240
A Prospective Randomized Double-Blind Trial Comparing 3 Doses of Intravenous Ketorolac for Pain Management
Source: ClinicalTrials.gov NCT02078492 ↗Enrolled (actual)
240
Serious AEs
0.0%
Results posted
Apr 2017
Primary outcomePrimary: Pain Score at 30 Minutes — 5.14; 5.05; 4.81 pain score
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
Hypothesis: Intravenous administration of Ketorolac in a dose of 10 mg is as effective in treating severe acute pain in patients presenting to the ED as 15 mg and 30 mg.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Pain Score at 30 Minutes |
5.14; 5.05; 4.81 | — |
| SECONDARY Adverse Effect of Dizziness |
14; 16; 12 | — |
| SECONDARY Adverse Effect of Nausea |
9; 11; 8 | — |
| SECONDARY Adverse Effect of Headache |
8; 2; 3 | .783 |
Eligibility Criteria
Inclusion Criteria
Severe flank and abdominal pain, severe musculoskeletal pain (traumatic and non-traumatic in origin), headache, dental pain.
Exclusion Criteria
Age >65, Active Peptic Ulcer disease, Acute Gastrointestinal Hemorrhage, Known Hx of Renal or Hepatic insufficiency, Hx of allergies to NSAIDS.
Data sourced from ClinicalTrials.gov (NCT02078492). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.